U.S. Markets open in 9 hrs 12 mins

PharmAthene announces U.S. patent for recombinant bioscavenger

PharmAthene announced that the U.S. Patent and Trademark Office issued U.S. patent number 8,729,245 to PharmAthene, with claims that cover methods for the production of its recombinant butyrlcholinesterase bioscavenger in mammalian cells.  PharmAthene is initially developing rBChE as a pre- and post-exposure therapy for military and civilian victims of nerve agent attacks.